NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
NeoImmuneTech
NeoImmuneTech
Inmune Bio, Inc.
Lokon Pharma AB
Bristol-Myers Squibb
University of Maryland, Baltimore
Cytovation AS
Advanced Accelerator Applications
Cytovation AS
Carrick Therapeutics Limited
Constellation Pharmaceuticals
Constellation Pharmaceuticals
Bristol-Myers Squibb
BioAtla, Inc.
University of California, San Diego
BeiGene
Anaveon AG
Palleon Pharmaceuticals, Inc.
PharmaMar
Hoffmann-La Roche
Thomas Jefferson University
Genelux Corporation
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Intensity Therapeutics, Inc.
BeiGene
Cyteir Therapeutics, Inc.
Ultimovacs ASA
Peking University Cancer Hospital & Institute
Daiichi Sankyo
Herlev Hospital
GlaxoSmithKline
Cantargia AB
Astex Pharmaceuticals, Inc.
Basilea Pharmaceutica
Servier
Kyowa Kirin Co., Ltd.
Jounce Therapeutics, Inc.
Advaxis, Inc.
Mural Oncology, Inc
National Cancer Institute (NCI)
University of Virginia
Steba Biotech S.A.
Capital Medical University
Capital Medical University
Capital Medical University
UMC Utrecht
CytomX Therapeutics
AstraZeneca
Apexigen America, Inc.
Processa Pharmaceuticals
National Institutes of Health Clinical Center (CC)